TTR · LNP, IV
Patisiran (Onpattro)
An approved siRNA therapeutic silencing TTR, indicated for hATTR amyloidosis (polyneuropathy). This page lists what the siRNA Atlas corpus holds on Patisiran and links to each primary document.
Identity
- Generic name
- Patisiran
- Brand name
- Onpattro
- Molecular target
- TTR
- Indication
- hATTR amyloidosis (polyneuropathy)
- Delivery
- LNP, IV
- FDA application
- NDA 210922
- Regulatory coverage
- FDA and EMA
Source documents in the corpus (5)
- FDAFDA prescribing information (current label)
- FDAFDA review
- FDAFDA multi-discipline review
- EMAEMA public assessment report (EPAR)
- EMAEMA product information (SmPC)
Every answer about Patisiran is drawn from these documents and the indexed literature, and cites the passage it used. Tables inside them are preserved, so numeric dosing, exposure and toxicology values stay searchable.
Ask the corpus about Patisiran
- →What is the approved dose and dosing interval of patisiran (Onpattro)?
- →Describe the clinical pharmacology and ADME of patisiran.
- →What did the regulatory reviews conclude about the nonclinical safety of patisiran?
- →Summarise the pivotal trial evidence for patisiran.
- →How does patisiran silence TTR, and how long does the effect last?
Other approved siRNA therapeutics
Information here is drawn from public regulatory records for reference and research. It is not medical advice — verify any clinical or regulatory decision against the current label and assessment report linked above.